Arvinas is a private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. Our proprietary PROTAC®, or Proteolysis-Targeting Chimera, works by inducing the cell’s own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins.
Building on groundbreaking research at Yale University by Craig Crews, Ph.D., Arvinas’ Founder and Chief Scientific Advisor, Arvinas has developed a broad technology platform focused on high value targets, with the potential to deliver safer, more potent treatment than small molecule inhibitors, and to address the 75% of targets that evade inhibition and are currently undruggable.
The Company’s therapeutic development is initially focused on developing degraders for high value targets in cancer, including androgen receptor and estrogen receptor. We have significant collaborations with Pfizer, Merck, and Genentech to leverage our PROTAC technology for additional targets, and are funded by leading venture capital firms in the biotechnology sector.